JAMAICA's Dr. Henry Lowe’s cancer research gets significant boost...."The molecule has consistently demonstrated its potential for the treatment of a variety of cancers, particularly lung, Non-Hodgkin's lymphoma, pancreatic, and prostate cancer," the news release said.
Thursday, October 29, 2015
JAMAICAN scientist Dr Henry Lowe and his research team have made another significant step in their efforts to successfully combat cancer under an exclusive licensing rights agreement with University of Maryland (UM) Ventures.
Dr. Ruel Lowe |
The university and Dr Lowe's Baltimore-based firm Educational and Scientific LLC (ESL) made the announcement yesterday in a news release, stating that the University of Maryland, Baltimore (UMB) granted ESL exclusive licensing rights to its interest in the commercial development of a molecule whose anticancer properties were jointly discovered by ESL and UMB.
Dr Lowe's Jamaica-based Bio-Tech R&D Institute collaborated on the discovery, which is being regarded in the scientific community as significant.
"The molecule has consistently demonstrated its potential for the treatment of a variety of cancers, particularly lung, Non-Hodgkin's lymphoma, pancreatic, and prostate cancer," the news release said.
Yesterday, the Jamaica Observer was told that the National Cancer Institute (NCI) has been evaluating the major drug molecule for efficacy and toxicity.
Educational and Scientific LLC is a commercial venture established by Dr Lowe to conduct further research and development of medicinal plant isolates for the development of new pharmaceutical and nutraceutical products.
UM Ventures is an initiative to channel the technical resources and research expertise of the University of Maryland by engaging partners in industry and social ventures to expand real world impact.
The entity explained that by encouraging students and faculty, and by providing expert advice and business services, more discoveries will reach the market.
It also said that by engaging directly with external partners, it will bring new investment, expanded markets and more start-up ventures.
Dr Lowe, who has spent nearly 50 years extensively studying the potential for plant-based compounds to treat a range of chronic diseases, has won international recognition for his work with the Jamaican Ball Moss (Tillandsia recurvata).
Properties from the plant have shown promise as potential treatment for cancers and as a neuroprotective agent, for diseases such as Parkinson's. more
Comments
Post a Comment